Author of

• 25924

  +

  P1.04 - Immunooncology (Not CME Accredited Session) (ID 936)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26460

    +

    P1.04-26 - Prospective Immuno-Biobank in NSCLC (ID 13831)

    16:45 - 18:00  |  Author(s): Aurelie Vuilleumier
    • Abstract
    • Slides

    Background
    

    Immune system could recognize tumor cells and eliminate them. T lymphocytes play an essential role in recognizing and lysing tumor cells. However, the humoral response (antibodies) seems also important. Recently, therapeutically progresses have been obtained with monoclonal antibodies that target inhibitory molecules expressed by T lymphocytes (anti-CTLA4, anti-PD1). Those antibodies induce reactivation or improvement of T lymphocytes’ lysing capacities. This clinical benefit can last for years and has been observed in several types of tumors. This is the beginning of a therapeutic revolution and hundreds of clinical trials are on-going with the objective of better exploitation of this strategy.

    Several steps are needed in order to increase the proportion of patients who benefit from immunotherapies.We currently do not understand completly the reason why an immune response could be efficient or not (spontaneously or after treatment), the respective role and interactions between humoral and cellular responses and mechanisms involved in the development of side effects observed in patients

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    All NSCLC patients who are candidate for Immunotherapy treatment regardless of staging and line of treatment cancer will be identified within our oncology department

    Blood sampling will be performed (50 to 100 ml) at severals time points: before any immunotherapy and repeated every 3 months or, in case of side effects or in case of extra-ordinary evolution.

    We will investigate cellular (T lymphocytes) and humoral (B lymphocytes) immune responses. We will also do a sequencing of the tumor in order to investigate genetic alterations. We will question the correlations between immune response and tumor pathological and molecular characteristic’s, as well as the impact of therapies administered to the patients on their immune response.

    4c3880bb027f159e801041b1021e88e8 Result
    

    We have recruited 12 patients so far, on treatment with immune check point inhibitor. We are going to perform another sampling 3 months after the beginning of the treatment (9 patients at the present time) Currently, we are continuing to reclute patients. The first analysis will be performed once we have 50 patients within the study and presented and the incoming meeting in November 2018
    

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    This is, as far as we know, the first prospectiveand ongoing immune- bio-bank in NSCLC patients that is going to provide valuable information to better understand the immunological changing at serological, tissue and genomic level induced by the immunotherapy in NSCLC and the possible mechanism of resistance or progression.
    

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.